JNJ7:45 AMJohnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platformjnj.com
JNJ12:35 PMJohnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravisPresentation / Abstractjnj.com
JNJ6:00 AMJohnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Floridajnj.com
JNJ6:33 AMNew TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myelomajnj.com
JNJ7:45 AMJohnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patientsjnj.com
JNJ2:03 AMIMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapiesjnj.com
JNJ8:00 AMJohnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platformjnj.com
JNJ12:04 AMJohnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 studyTrial Results • Phase 2jnj.com
JNJ12:03 AMJohnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's diseasejnj.com
JNJ8:29 AMRYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limitedjnj.com
JNJ8:27 AMJohnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigmjnj.com
JNJ2:00 PMRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancerjnj.com
JNJ8:18 AMNew TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myelomajnj.com
JNJ7:10 PMFDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damagejnj.com
JNJ4:01 PMGroundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovationjnj.com
JNJ7:45 AMJohnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheterjnj.com
JNJ4:34 PMJohnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conferencejnj.com
JNJ8:00 AMJohnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCPjnj.com
JNJ8:00 AMJohnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remissionjnj.com
JNJ8:05 AMJohnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's diseasejnj.com
JNJ8:05 AMJohnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel diseasejnj.com
JNJ7:00 AMJohnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic Systemjnj.com
JNJ8:00 AMCAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysisjnj.com
JNJ8:30 AMJohnson & Johnson ushers in the next wave of innovation in cancer care with more than 20 clinical and real-world studies at ASCO 2026jnj.com
JNJ4:33 PMJohnson & Johnson to Participate in the Bernstein’s 42nd Annual Strategic Decisions Conferencejnj.com
JNJ8:05 AMFDA approves CAPLYTA® (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophreniajnj.com
JNJ8:03 AMFDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)jnj.com
JNJ8:05 AMIMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)jnj.com
JNJ4:22 PMJohnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conferencejnj.com
JNJ7:45 AMJohnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026jnj.com
JNJ6:21 AMJohnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%jnj.com